- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
GE names new MRI executives
GE Medical Systems of Milwaukee has made several changes to theexecutive line-up of its MRI division. Morry Blumenfeld has beennamed general manager of advanced MR development. Blumenfeld willoversee GE's MR-guided surgery effort and will manage
GE Medical Systems of Milwaukee has made several changes to theexecutive line-up of its MRI division. Morry Blumenfeld has beennamed general manager of advanced MR development. Blumenfeld willoversee GE's MR-guided surgery effort and will manage programson special-purpose MRI systems, new magnet configurations, andnew clinical applications. Blumenfeld previously oversaw GE'sdevelopment of its 0.5-tesla open interventional MRI scanner.
In addition to Blumenfeld's appointment, GE has named YoshiakiFujimori as global general manager of GE's MRI business, replacingNobuhiko Ito. Fujimori previously headed GE's global CT business.
In other GE news, the vendor said that it has signed an agreementwith Opgal Optronic Industries of Karmiel, Israel, that givesGE distribution and service rights to a new line of cardiac imagingequipment. The products will be used by cardiac surgeons to makesure that grafted blood vessels used in bypass operations arefunctioning properly before open heart surgery is performed.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
